We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin. < 10. g/dL). Patients (n= 29; 18 RBC-transfusion dependent) received 0.5. mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21%) patients responded (median response duration 11.4 months), including four who achieved RBC-transfusion-independence per the Delphi criteria and two who achieved clinical improvement (in platelets and spleen, respectively) per the International Working Group for Myelofibrosis Research and Treatment criteria. Grade 3 toxicity occurred in 1 patient (fatigue). Pomalidomide with prednisone is safe therapy with modest activity in patients with MF and anemia. ClinicalTrials.gov Identifier: NCT00946270.
|Original language||English (US)|
|Number of pages||4|
|State||Published - Sep 2014|
ASJC Scopus subject areas
- Cancer Research